Brief: OBSEVA: Phase 2 Results Of Obe022 Expected In H2 2020

Obseva SA

15/01/2020 06:06

Jan 15 (Reuters) - OBSEVA SA  OBSN.S :
    * PHASE 3 LINZAGOLIX TRIALS EXPECTED TO GENERATE ADDITIONAL
DATA
IN UTERINE FIBROIDS IN Q2:20 WITH FIRST LINZAGOLIX REGULATORY
FILING PLANNED FOR LATE 2020
    * ENROLLMENT OF LINZAGOLIX US AND EU PHASE 3 TRIALS IN
ENDOMETRIOSIS ON TRACK
    * PHASE 2 RESULTS OF OBE022 EXPECTED IN 2H:20

Source text for Eikon:  ID:nGNEm4jpv 
Further company coverage:  OBSN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))